

Cryptosporidiosis among HIV-infected persons in the Niger Delta of Nigeria

1. Erhabor O., 2. Obunge O., 2. Awah I.

Antiretroviral therapy programme 1. Department of Haematology & 2. Department of Medical Microbiology and Parasitology
University of Port Harcourt Teaching Hospital P.M.B. 6173 Port Harcourt Nigeria.

ABSTRACT

BACKGROUND: Since the discovery of acquired immunodeficiency syndrome (AIDS), many studies demonstrated that intestinal parasites were frequently associated with pictures of severe diarrhoea in patients with HIV.

OBJECTIVES: To determine the prevalence of Cryptosporidiosis among HIV-infected persons in the Niger Delta of Nigeria.

METHOD: Faecal samples from One hundred and five HIV/AIDS infected subjects made up of 48 males and 57 females aged 18-54 years, mean age and CD4 count of 36.14 ± 8.46 years and 320 ± 140 cells/ μ l respectively were evaluated for Cryptosporidiosis using the Modified Ziehl-Neelsen staining method.

RESULTS: Of the one hundred and five faecal samples examined, 3(2.9%) were positive for cryptosporidium oocyst. Prevalence was significantly higher among females 2/57 (3.5%) compared to males 1/48(2.1%), among subjects with diarrhoea 3(11.5%) and among subjects with CD4 lymphocyte count <200 cells/ μ l ($p<0.01$). CD4 count of subjects positive for cryptosporidium oocyst was significantly lower (150 ± 50 cells/ μ l). The mean CD4 count of subjects with diarrhoea was significantly lower (mean 180 cells/ μ l) compared to those without diarrhoea (360 cells/ μ l).

CONCLUSION: Our study indicates that the prevalence of intestinal colonization due to Cryptosporidium is significantly higher among HIV-infected persons presenting with diarrhoea and low CD4 lymphocyte count of <200 cells/ μ l and re-emphasizes the need to incorporate routine faecal parasitological examination (FPE) in the follow up management of patients with HIV/AIDS. This is likely to optimise treatments in these patients by eradicating opportunistic pathogens and improve the quality of life of these patients.

KEY WORDS: Cryptosporidiosis, HIV, AIDS, Niger Delta, Nigeria.

INTRODUCTION

Cryptosporidium is a protozoan that produces environmental stage (oocysts) that are eliminated in the faeces of the host. This parasite is a common cause of

acute gastroenteritis in humans particularly those that are immunocompromised¹. Human infection is usually acquired by direct contact between persons and by ingestion of contaminated food or water². *Cryptosporidium* has a wide host range (reptiles, birds and mammals) and a wide geographical distribution in developing and developed countries³. Chronic diarrhoea is a common presentation among HIV-infected Africans^{4,5}. *Cryptosporidium* is the commonest microbial cause of diarrhoea in the HIV-infected population worldwide⁶.^{7,8} Laboratory diagnosis is usually made by microscopic detection of microsporidial spores in faecal samples stained by a modified Ziehl-Neelsen method⁹. *Cryptosporidiosis* causes significant morbidity and mortality in human immunodeficiency virus (HIV)-infected population. In June 2002 antiretroviral therapy of two nucleoside reverse transcriptase inhibitors (stavudine and lamivudine) and one non-nucleoside (nevirapine) became available for HIV-infected patients in Nigeria. In this study in the Niger Delta Geopolitical zone of Nigeria, we sought to assess the prevalence of *Cryptosporidiosis* in our cohort of human immunodeficiency virus (HIV)-infected adults.

MATERIALS AND METHOD

Between February 2005 and March 2006, we selected 105, consecutively recruited previously antiretroviral naive HIV/AIDS patients. They were enrolled into phase 3 antiretroviral therapy project in the Department of Haematology of the University of Port Harcourt Teaching Hospital (UPTH). This is a tertiary health facility with 500 beds, located in the Niger Delta geopolitical zone of Nigeria. Inclusion criteria included age ≥ 18 years, confirmed HIV positivity and written informed consent to enrol in the study. Subjects responded to standard questionnaire. Socio-demographic information (age, sex, educational status, previous antiretroviral and other anti-infective medications use 30 days prior to enrolment). Written informed consent was obtained from all study subjects. Subjects submitted faecal specimen for faecal parasitological examination at the Microbiology and Parasitology Department of University of Port Harcourt Teaching Hospital. Smears of faecal samples were prepared and stained using the Modified Ziehl-Neelsen staining. Previous study found method cost effective particularly in resource-limited setting¹⁰. They were read with a light microscope; including all of the fields of eight to ten slides per faecal specimen. Slides were

considered positive when showing *Cryptosporidium* oocysts. Complementary CD4+ T lymphocyte counts of subjects were obtained using the Dynal beads method (Dynal Asa, Oslo, Norway) -an alternative to flow cytometry for the enumeration of peripheral CD4 T-lymphocyte particularly in resource poor settings. Previous study showed a positive correlation with results from flow cytometry¹¹.

STATISTICAL ANALYSIS

Parametric and non-parametric methods were utilized in uni- and multivariate analyses. The maximum level of significance utilized for the statistical analyses was 5%. The analyses were carried out using the program "Statistical Package for Social Sciences" (SPSS Inc., Chicago, IL), version 9.

RESULTS

The highest prevalence was observed in subjects in the 30-39 years age group (6.6%) followed by the 20-29

years age group (3.6%) as shown in table 1. The study population was made up of 48 males and 57 females aged 18-54 years, mean age and CD4 count of 36.14 ± 8.46 years and 320 ± 140 cells/ μ l respectively. Figure 1 shows the gender-related distribution of cryptosporidiosis among HIV-infected subjects. Of the faecal samples examined, 26(24.8%) was diarrhoeic while 79(75.2%) were non-diarrhoeic. The mean CD4 count of subjects with diarrhoea was significantly lower (mean 180 cells/ μ l) compared to those without diarrhoea (360 cells/ μ l). Of the 105 faecal samples examined 3(2.9%) was positive for *Cryptosporidium* oocysts. Prevalence was significantly higher among females 2/57 (3.5%) compared to males 1/48(2.1%), among subjects with diarrhoea 3(11.5%) and among subjects with CD4 lymphocyte count <200 cells/ μ l 3/18(16.6%) ($p < 0.01$). The mean CD4 count of subjects positive for *Cryptosporidium* oocyst was 150 ± 50 . Table 2 shows the mean values of subjects with diarrhoea and those without diarrhoea.

Table 1: Age Distribution of study population

Age group (years)	Total screened	Number positive for cryptosporidiosis	% Positive
>20	15	-	-
20-29	28	1	3.6
30-39	30	2	6.6
40-49	18	-	-
50-59	14	-	-


Table 2: Mean values of diarrhoeic and non-diarrhoeic HIV/AIDS-infected subjects.

Parameter	Diarrhoeic subjects	Non-diarrhoeic subjects	P-value
Age	32.54 ± 8.40	31.33 ± 5.32	> 0.05
CD4+ Count	180 ± 90	360 ± 100	<0.01

DISCUSSION

In this study of HIV-infected adults in Port Harcourt Nigeria, the overall prevalence of *Cryptosporidium* oocysts was 2.9%. *Cryptosporidium* infection was found clustered among HIV/AIDS patients presenting with diarrhoea. This prevalence is consistent with findings from previous studies in different parts of the world among patients with HIV¹²⁻¹⁵ but however at variance with previous reports by Kamisky *et al* in Honduras¹⁶ and Nwokediuko *at al* in Nigeria¹⁷ who did not find *Cryptosporidium* species among 133 and 161 HIV infected Hondurans and Nigerians respectively. It is possible that a significant number of subjects included in these studies may have been on anti-infective medication prior to the study coupled with the fact that subjects may not have presented with low AIDS defining CD4 Lymphocyte count as observed in our study. There seems to be a correlation between HIV and

Figure 1: Gender-related distribution of *Cryptosporidium* infection among HIV-infected subjects.



Cryptosporidial infection. Studies from other parts of the globe on HIV/AIDS-related diarrhoea have implicated *Cryptosporidium*; Taiwan (0.5%)⁶, India (33%)¹⁴ and Brazil (8.1%)¹⁸. The first reports of human cases of *Cryptosporidiosis* were in 1976¹⁹ followed over the next four years by a handful of reports largely of disease in immunosuppressed host. However, the Centres for disease control (CDC) in the USA recognized the importance of *Cryptosporidium* as a major human pathogen in 1982 when outbreak of cryptosporidial diarrhoea in 21 patients with advanced HIV disease²⁰. Chronic *Cryptosporidiosis* is a qualifying diagnosis for CDC-defined AIDS. In the United States 3-4% of persons at the time of CDC defined AIDS diagnosis have *Cryptosporidiosis* and an estimated 10-15% develop *Cryptosporidiosis* during the course of HIV disease²¹. In Sydney Australia, 5% of patients with advanced HIV disease undergoing gastrointestinal evaluation have *Cryptosporidium* enteritis²².

The prevalence of cryptosporidiosis was significantly higher among HIV/AIDS-infected patients with AIDS defining CD4 lymphocyte count of <200cells/μl. This finding is consistent with previous reports in Cameroon⁷ by Sarfati *et al* who observed a significantly higher prevalence of opportunistic protozoa (32%) among patients with CD4 cell counts less than 50cells/μl and Dwivedi *et al*¹⁴ in India who found enteric coccidian parasites significant associated with diarrhoea, especially among those a lower CD4+ cell count. Infection with HIV causes a gradual decline in the peripheral CD4 helper lymphocyte. These lymphocytes are part of the body's immune system and play a key role in cell mediated immunity. But as HIV destroys these lymphocytes, HIV-infected patients becomes predisposed to opportunistic infections. HIV/AIDS related cryptosporidial infection has been found to resolve following HAART related immune reconstitution of the immune system even without specific treatment of the parasite²³⁻²⁴. Moreover there is evidence invitro and invivo to suggest that the control of *Cryptosporidiosis* in patients on HAART are also helped by the anti-HIV protease inhibitors which could be acting on the aspartyl-protease of the parasite²⁵. Highly active antiretroviral therapy has changed the landscape of HIV/AIDS related care in the developed world in patients fortunate enough to have access but its long-term effect has not been well elucidated by many HIV/AIDS infected in Nigeria. There is need for the universal access to HAART in resource limited setting particularly in the Niger Delta geopolitical zone of Nigeria. This will facilitate the initiation of therapy in these patients before they develop full blown AIDS, their CD4 lymphocyte count fall below 200cells/μl and they become prone to a wide range of opportunistic infection including cryptosporidiosis. There is need to incorporate routine faecal parasitological examination (FPE) in the follow up management of patients with HIV/AIDS. This is likely to optimise treatments in these patients by eradicating opportunistic pathogens and improve the quality of life of these patients. This study had several limitations; the non availability of PCR based technology in our centre to characterize the three samples found positive for Cryptosporidiosis as well as compare techniques employed in this study with molecular techniques.

REFERENCES

1. Ramakrishnan K, Shenbagarathai R, Uma A, Kavitha K, Rajendran R, Thirumalaikolundusubramanian P. Prevalence of intestinal parasitic infestation in HIV/AIDS patients with diarrhoea in Madurai City, South India. *Jpn J Infec Dis*, 2007; 60(4):209-210.
2. Fayer R, Morgan U, Upton SJ. Epidemiology of Cryptosporidium: transmission, detection and identification. *Int J Parasit*, 2000; 30:1305-1322.
3. Crawford FG, Vermunda SM. Human Cryptosporidiosis. *Crit Rev Microbiol* 1988; 16:159.
4. Habib AG, Onyemelukwe GC, Kangave D. Clinical presentation of HIV infection in Northern Nigeria and its relationship to CD4 + T-cell count. *Nigerian Medical Practitioner* 1998; 35:3-8.
5. Khumalo-Ngwenya B, Luo NP, Chintu C, Senke R, Sakala-Kazembe F, Baboo KS, *et al*. Gut parasite in HIV-seropositive Zambian adults with diarrhoea. *African Medical Journal* 1994; 71:379-382.
6. Hung CC, Tsaihong JC, Lee YT, Deng HY, Hsiao WH, Chang SY, Chang SC, Su KE. Prevalence of intestinal infection due to Cryptosporidium species among Taiwanese patients with human immunodeficiency virus infection *Formos Med Assoc* 2007; 106(1):31-35.
7. Sarfati C, Bourgeois A, Menotti J, Liegeois F, Moyou-Somo R, Delaporte E, Derouin F, Ngole EM, Molina JM. Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study. *Am J Trop Med Hyg* 2006; 74(1):162-164.
8. Stark D, Fotedar R, Van Hal S, Beebe N, Marriott D, Ellis JT, Harkness J. Prevalence of enteric protozoan in human immunodeficiency virus (HIV)-positive men who have sex with men from Sydney, Australia. *Am J Trop Med* 2007 Mar; 76(3):549-552.
9. Casemore DP. Laboratory method for diagnosis of Cryptosporidiosis. *J Clin Pathol* 1991; 44:455-456.
10. Ravn P, Lungren JD, Lusakumuni K, Nelson AM. Persistent diarrhoea in Zairian AIDS patients. *BMJ* 1991; 302:277-280.
11. Diabougua S, Chazallon C, Kazatchkin MD. Successful implementation of a low cost method for the enumerating CD4 T-lymphocyte in resource-limited settings: the ARNS 12-26 study. *AIDS* 2001; 17:2201-2208.
12. Gatei W, Barrett D, Lindo JF, Eldemire-Shearer D, Cama V, Xiao L. Unique Cryptosporidium population in HIV-infected persons, Jamaica. *Emerg Infect Dis* 2008; 14(5):841-843.
13. Rao Ajjampur SS, Ssirvathan JR, Muthusamy D, Gladstone BP, Abraham OC, Mathai D, Ward H, Wanke C, Kang G. Clinical features & risk factors associated with cryptosporidiosis in HIV infected adults in India. *Indian J Med Res* 2007; 126(6):553-557.
14. Dwivedi KK, Prasad G, Saini S, Mahajan S, Lal S, Baveja UK. Enteric opportunistic parasites among HIV infected individuals: associated risk factors and immune status. *Jpn J Infec Dis* 2007; 60(2-3):76-81.
15. Andualem B, Kassu A, Moges F, Gedefaw M, Diro E, Mengistu G, Andargie G. Diarrhoea-associated parasites in HIV-1 seropositive and sero-negative patients in a teaching hospital, Northwest Ethiopia. *Hiop*

Med J 2007; 45(2):165-170.

16. Kaminsky RG, Soto RJ, Campa A, Baum MK. Intestinal parasitic infections and eosinophilia in an human immunodeficiency virus positive population in Honduras. *Mem Inst Oswaldo Cruz* 2004; 99:773-778.
17. Nwokediuko S.C., Bojuwoye B.J., Onyenekwe B. Apparent rarity of cryptosporidiosis in human immunodeficiency virus (HIV)-related diarrhea in Enugu, south-Eastern, Nigeria. *Nig Postgrad Med J* 2002; 9:70-3.
18. Tatiana Paschoalette RB, Josias MV, Ivo Castelo BC, Telma Regia BS, Cristina de Souza C. Enteric parasitic infections in HIV/AIDS patients before and after highly active antiretroviral therapy. *Braz J Infec Dis*. 2008; 12(2):115-122.
19. Meisel JL, Perara DR, Meligo C. Overwhelming watery diarrhoea associated with cryptosporidium in an immunosuppressed patient. *Gastroenterol* 1976; 70:1156-1160.
20. Centers for Disease Control. Cryptosporidiosis: assessment of chemotherapy of males with acquired immune deficiency syndrome (AIDS). *MMWR* 1982; 31:334-338.
21. Soave R. Cryptosporidiosis and Isosporiasis in patients with AIDS. *Infec Dis Clin North Am* 1988; 20:1421-1428.
22. Colebunders R, Lusakumuni K, Nelson AM. Persistent diarrhoea in Zairian AIDS Patients: endoscopic and histologic study. *Gut* 1988; 29:1687-1691.
23. Maggi P., Larocca A.M., Quarto M., et al. Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. *Eur J Clin Microbiol Infect Dis* 2000; 19:213-7.
24. Carr A., Marriot D., Field A., et al. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. *Lancet* 1998; 351:256-61.
25. Pozio E., Gomez Morales M.A. The impact of HIV-protease inhibitors on opportunistic parasites. *Trends Parasitol* 2005; 21:58-63.
26. Escobedo A.A., Nunez F.A. Prevalence of intestinal parasites in Cuban immunodeficiency syndrome (AIDS) patients. *Acta Trop* 1999; 72:125-130.